参考文献
1. Mahoney FJ. update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol. Rev, 1999, 12(2): 351–366.
2. Ganes C. Vieuses and interferons. Annu Rev Microbiol,2000,32:866-867.
3. Suxuki F, Tsubota A, Akuta N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing buring longterm lamivudine therapy. J Gastroenterol,2002,37(11) :922-927.
4. Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology ,2003, 38(3): 545–553.
5. Angus P, Vaughan R, Xiong S,et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003,125(2): 292–297.
6. Tenney DJ, Levine SM, Rose RE,et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004, 48(9): 3498–3507.
7. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 2002, 37(3): 366–369.
8. 庞小峰.生命体吸收的红外光的非热生物效应的研究.物理,2001,30(9):525-532.
9. Gagliardi S, Atlante A, P
上一页 [1] [2] [3] [4] [5] [6] 下一页
对此文章有什么疑问,请提交在乙肝论坛